Source-grounded facts extracted from DarioHealth Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
DarioHealth Corp. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at $20,000,000 (effective 2026-03-30).
“On March 30, 2026, DarioHealth Corp., a Delaware corporation (the “Company”), entered into a sales agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”), pursuant to which the Company may issue and sell, from time to time, up to an aggregate of $20,000,000 of shares of its common stock”
DarioHealth Corp.: Amended and Restated Certificate of Incorporation to expressly authorize the Board of Directors to alter and repeal the company's bylaws, subject to stockholder power (effective 2026-02-02).
“On February 2, 2026, DarioHealth Corp. (the “Company”) filed an Amended and Restated Certificate of Incorporation (“Amended Charter”) with the Secretary of State of the State of Delaware amending the Company’s Certificate of Incorporation to expressly authorize the Company’s Board of Directors to alter and repeal the Company’s bylaws, subject to the power of the Company’s stockholders to alter or repeal the bylaws.”
DarioHealth Corp.: Amended Series C-1 Certificate of Designation to accelerate mandatory conversion period (effective 2025-09-25).
“On September 25, 2025, the Company, upon obtaining the vote of a majority of the holders of the relevant classes of preferred stock and the approval of the Company’s Board of Directors, filed an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company’s Series C-1 Preferred Stock (the “Series C-1 Certificate of Designation”) with the Secretary of State of the State of Delaware. The Series C-1 Certificate of Designation was amended to accelerate the mandatory conversion period of all outstanding shares of such series into shares of the Company’s common stock, or at each holder’s election in pre-funded warrants, effective as of September 25, 2025.”
DarioHealth Corp.: Amended and restated certificates of designation for Series A-1, Series C, C-2, D, D-1, D-2, and D-3 preferred stock to accelerate mandatory conversion period and provide option for pre-funded warrants (effective 2025-09-18).
“On September 18, 2025, DarioHealth Corp. (the “Company”), upon obtaining the vote of a majority of the holders of the relevant classes of preferred stock and the approval of the Company’s Board of Directors, filed an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company’s Series A-1 Preferred Stock (the “Series A-1 Certificate of Designation”), an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company’s Series C Preferred Stock (the “Series C Certificate of Designation”), an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company’s Series C-2 Preferred Stock (the “Series C-2 Certificate of Designation”, collectively with the Series C Certificate of Designation, the “Series C Certificates of Designation”), an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Company’s Series D Preferred Stock (the “Series”
DarioHealth Corp.: The company amended its certificate of incorporation to effect a 20-for-1 reverse stock split, effective August 28, 2025 (effective 2025-08-28).
“Effective as of August 28, 2025, DarioHealth Corp. (the “Company”) will effect a reverse stock split of its outstanding shares of common stock at a ratio of twenty -for- one (the “Reverse Split”).”
Chen Franco-Yehuda was appointed as Chief Financial Officer, Treasurer and Secretary at DarioHealth Corp..
“On April 18, 2025, the Board of Directors of the Company appointed Chen Franco-Yehuda, age 41, to serve as the Company’s Chief Financial Officer, Treasurer and Secretary, effective as of May 15, 2025.”
Zvi Ben-David resigned as Chief Financial Officer, Treasurer and Secretary at DarioHealth Corp..
“On April 18, 2025, Mr. Zvi Ben-David resigned as Chief Financial Officer, Treasurer and Secretary of DarioHealth Corp. (the “Company”), effective as of May 15, 2025.”
Jon Kaplan resigned as member of the Board at DarioHealth Corp..
“On February 24, 2025, Jon Kaplan voluntarily resigned from his position as a member of the Board.”
Lawrence Leisure was appointed as member of the Board at DarioHealth Corp..
“On February 25, 2025, on the recommendation of the Nominating Committee of the Board of Directors, or the Board, of DarioHealth Corp., or the Company, appointed Lawrence Leisure as a member of the Board, effective immediately.”
Richard Anderson departed as President at DarioHealth Corp..
“the Company and Richard Anderson, the Company’s President, mutually agreed for Mr. Anderson to cease serving in his role as President of the Company.”
Steven Nelson was appointed as Chief Commercial Officer at DarioHealth Corp..
“appointed Steven Nelson, age 51, to serve as its Chief Commercial Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.